OTOFIX Introduces the D1 Lite Diagnostic Tool, Purpose-Built for Small Garage Technicians
OTOFIX has launched the D1 Lite, a compact diagnostic tool available at otofix.store, offering professional-grade features for small garages and mobile technicians at an accessible price.
OTOFIX has just introduced the D1 Lite, a compact diagnostic tool designed for small garages, mobile technicians, and students in training. Available at https://otofix.store, it offers key diagnostic features typically found in higher-end models at a price point meant to support independent repair professionals and learners alike.
Backed by Autel, a globally trusted name in automotive diagnostics, the D1 Lite provides full-system scans, live data, active component tests, and more, all in a lightweight, easy-to-use device priced under $400.
Professional-Grade Capabilities in a Compact Format
With a slim build, bright orange shell, and HD touchscreen, the D1 Lite is designed to be simple to carry and operate. It supports over 100 car brands and includes more than 38 service functions, such as:
Oil reset
Brake system maintenance (EPB)
Battery management (BMS)
Diesel particulate filter (DPF) service
Factory-level full-system diagnostics
These functions help technicians perform everyday maintenance tasks quickly and accurately. Whether it's preparing a vehicle for a customer handoff or troubleshooting a warning light, the D1 Lite gives users control over key systems beyond just the engine. It can access ABS, airbags, transmission, HVAC, immobilizer systems, and more—making it a complete diagnostic companion.
It also includes over 3,000 active tests, allowing users to trigger components like fuel pumps, cooling fans, mirrors, windows, and seat motors to confirm function during diagnostics. These bidirectional capabilities are usually found in tools that cost far more.
Reliable Vehicle History Checks with VIN and Odometer Data
One of the most useful features is the VIN/Odometer Check. This function reads the vehicle identification number and mileage from different control units in the car. It helps detect mismatches or irregular readings that could point to tampering or system errors. This feature is especially helpful for inspecting used cars or verifying system integrity.
It supports many popular vehicle brands, including Toyota, VW, Ford, BMW, Hyundai, Mercedes-Benz, Kia, Subaru, Fiat, Audi, and Land Rover. For garages that often work on pre-owned vehicles, this adds a layer of transparency and helps flag inconsistencies early.
Advanced Protocol Support for Modern Vehicle Systems
The D1 Lite includes advanced protocols to support today's automotive systems. It works with CAN FD and DoIP, both of which are communication protocols adopted by newer vehicles to allow faster data exchange between modules. These technologies are essential for working on 2021 and newer models from brands like GM, Hyundai, BMW, and Mercedes-Benz.
It also includes FCA AutoAuth, which provides secure access to Chrysler, Jeep, Dodge, Fiat, and Alfa Romeo systems without requiring additional tools . This lets users scan newer vehicles with locked gateways and still perform full diagnostics and service functions.
Auto VIN detection further speeds up the workflow by identifying the vehicle instantly, reducing manual entry and potential errors.
Two Years of Free Software Updates Included
Unlike many scan tools that charge ongoing subscription fees, the D1 Lite comes with two years of free software updates. This helps users keep up with new vehicle models and functions without added costs. The included updates are valued at 718 dollars, providing long-term value right out of the box.
These updates are delivered over Wi-Fi and take just minutes to install, ensuring users always have the latest coverage and bug fixes. After the two-year period, continued updates remain optional—not required to keep using the tool.
Designed for Technicians, Trainees, and Mobile Repair Pros
The D1 Lite was built with everyday users in mind. It is a good fit for:
Independent garages that need professional tools at a fair price
Mobile mechanics who want something durable and easy to carry
Trade school students learning diagnostics on real vehicles
Tool resellers who need a reliable and approachable product to offer
For those looking to move up from entry-level scanners or transition from analog to digital, this tool provides the right balance of features and price. There's no steep learning curve, no hidden subscriptions, and no wasted time trying to interpret incomplete scan results.
Backed by Autel's Diagnostic Expertise
OTOFIX is a sub-brand of Autel, a company known worldwide for its automotive diagnostic systems. The D1 Lite benefits from the same development expertise, software reliability, and product support as Autel's professional-grade tools. Positive reviews from technicians highlight its ease of use and time-saving capabilities in real-world repair jobs.
A Smart Investment for Growing Garages
The OTOFIX D1 Lite delivers the essential diagnostic features typically found in higher-end tools, but in a format that's accessible, efficient, and easy to use. For small teams and independent technicians looking to upgrade their capabilities without overspending, it offers a smart, practical solution. More details, including availability and specifications, can be found at otofix.store.
Contact & Follow Us
Website: https://otofix.store
Follow us on social media:
Facebook: facebook.com/otofixtech
YouTube: youtube.com/@otofix9536
Media Contact
Company Name: Shenzhen Lianke Technology Development Co., Ltd.
Contact Person: Amber Qiu
Email: Send Email
Country: China
Website: https://otofix.store
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
an hour ago
- Globe and Mail
Toll Brothers Announces Grand Opening of Clubhouse Amenities at its Regency at Holly Springs Community in Holly Springs, North Carolina
HOLLY SPRINGS, N.C., June 25, 2025 (GLOBE NEWSWIRE) -- Toll Brothers, Inc. (NYSE:TOL), the nation's leading builder of luxury homes, today announced the grand opening of the highly anticipated community clubhouse and resident amenities at Regency at Holly Springs, a premier 55+ active-adult community located in Holly Springs, North Carolina. Set in desirable Holly Springs, with easy access to Cary and Apex, this 55+ active adult Regency community by Toll Brothers redefines luxury living in a premier location. Regency at Holly Springs offers endless options for socialization and relaxation with private amenities just for Regency residents. The newly opened onsite amenities include a resort-style pool, clubhouse, state-of-the-art fitness center, and pickleball and bocce courts, plus social membership to 12 Oaks Country Club with its beautiful golf course, restaurant, trails, garden, and more. 'Regency at Holly Springs is an exceptional community that offers a luxurious, low-maintenance lifestyle with an abundance of amenities,' said Ted Pease, Division President of Toll Brothers in Raleigh. 'We are thrilled to unveil the new clubhouse and amenities that will serve as the heart of the community, fostering connections and providing residents with a place to gather and enjoy their favorite activities.' Home shoppers can select from an array of thoughtfully designed luxury homes with first-floor primary bedroom suites. Two collections of homes offer single-family home designs with 1,680 to over 2,900 square feet, 2 to 3 bedrooms, and 2 to 4 baths. Homes are priced from the mid-$500,000s. Toll Brothers customers will experience one-stop shopping at the Toll Brothers Design Studio. The state-of-the-art Design Studio allows customers to choose from a wide array of selections to personalize their dream home with the assistance of Toll Brothers professional Design Consultants. Regency at Holly Springs offers convenient access to U.S. Route 1 and North Carolina Highway 540 for quick drives to downtown Raleigh or Durham for shopping, dining, and entertainment. The community also offers convenient access to the vibrant downtowns of Holly Springs, Fuquay-Varina, Cary, and Apex — each known for their unique blend of charming boutiques, exceptional dining, and inviting local shops. For more information on Regency at Holly Springs and other Toll Brothers communities in North Carolina, call (844) 840-5263 or visit About Toll Brothers Toll Brothers, Inc., a Fortune 500 Company, is the nation's leading builder of luxury homes. The Company was founded 58 years ago in 1967 and became a public company in 1986. Its common stock is listed on the New York Stock Exchange under the symbol 'TOL.' The Company serves first-time, move-up, empty-nester, active-adult, and second-home buyers, as well as urban and suburban renters. Toll Brothers builds in over 60 markets in 24 states: Arizona, California, Colorado, Connecticut, Delaware, Florida, Georgia, Idaho, Indiana, Maryland, Massachusetts, Michigan, Nevada, New Jersey, New York, North Carolina, Oregon, Pennsylvania, South Carolina, Tennessee, Texas, Utah, Virginia, and Washington, as well as in the District of Columbia. The Company operates its own architectural, engineering, mortgage, title, land development, smart home technology, and landscape subsidiaries. The Company also develops master-planned and golf course communities as well as operates its own lumber distribution, house component assembly, and manufacturing operations. Toll Brothers has been one of Fortune magazine's World's Most Admired Companies™ for 10+ years in a row, and in 2024 the Company's Chairman and CEO Douglas C. Yearley, Jr. was named one of 25 Top CEOs by Barron's magazine. Toll Brothers has also been named Builder of the Year by Builder magazine and is the first two-time recipient of Builder of the Year from Professional Builder magazine. For more information visit From Fortune, ©2025 Fortune Media IP Limited. All rights reserved. Used under license. Photos accompanying this announcement are available at
Globe and Mail
2 hours ago
- Globe and Mail
The Tile Shop Expands Exclusive Collaboration With Jeffrey Alan Marks, Launching Two New Coastal-Inspired Designs
MINNEAPOLIS, June 25, 2025 (GLOBE NEWSWIRE) -- The Tile Shop, a leading specialty retailer of natural stone and specialty tiles, is proud to announce the expansion of its exclusive Jeffrey Alan Marks Collection with the debut of two new tile designs: Natural Zen Birchwood and Sand Dollar. These new designs reflect Marks' signature California-casual aesthetic and offer customers elevated options for creating timeless, relaxed spaces with natural texture and coastal-inspired hues. With a palette of soft blue, sand, and white tones, the collection captures the calming rhythm of the coast. 'With Natural Zen Birchwood and Sand Dollar, I wanted to create tiles that feel grounded, organic and refined, like the shimmer of the sea,' says Jeffrey Alan Marks. "My time spent in nature every day in the Santa Barbara mountains and Summerland beaches inspires the laid-back feel my tile collections bring to the home, anchoring the space for casual living." 'Working with Jeffrey is always an inspiring, collaborative process,' says Kirsty Froelich, Senior Director of Design and Product Development at The Tile Shop. 'He brings a clear point of view—elegant, approachable and deeply rooted in natural materials—and we work closely to translate that into tile in a way that feels both design-forward and easy to live with. Natural Zen Birchwood and Sand Dollar add beautiful dimension and versatility to the collection. We're so excited to offer our customers even more ways to bring Jeffrey's relaxed, coastal style into their homes.' About the Designs Natural Zen Birchwood Available colors: White, Sea Blue and Ash Inspired by the simplicity of Japanese spa design, Natural Zen Birchwood is a 4' x 16' ceramic tile with soft, neutral tones and subtle dimensional texture. The understated, organic elegance of this glossy wall tile makes it ideal for serene bathrooms, backsplashes or wellness-inspired spaces. Sand Dollar Available colors: Ocean and Ash Add a touch of seaside serenity to walls and floors with the intricate motif and sunwashed coloring of this 6" x 6" matte porcelain tile. With a pattern reminiscent of hand-painted designs, Sand Dollar infuses any room with the relaxed elegance of coastal living. The expanded Jeffrey Alan Marks Collection is available now at The Tile Shop's more than 140 retail locations nationwide and at This exclusive collection is part of The Tile Shop's growing roster of exclusive designer collaborations, including partnerships with Nikki Chu, Kelli Fontana, Alison Victoria and Laura Park (coming summer 2025), as well as iconic British brands Laura Ashley and Morris & Co. These exclusive offerings are only available at The Tile Shop, bringing designer vision and premium materials together in one destination for tile. ABOUT JEFFREY ALAN MARKS Jeffrey Alan Marks' design work is infused with equal parts good nature and good taste. Recognized as one of today's most influential American designers, Jeffrey begins each project with an effortless sense of timelessness, and then infuses each space with casual livability. Devoid of trend or artifice, Jeffrey provides what today's consumer is craving: products and places connected to craft that are more meaningful and more accessible. ABOUT THE TILE SHOP Tile Shop Holdings, Inc. (Nasdaq: TTSH) is a leading specialty retailer of natural stone, man-made and luxury vinyl tiles, setting and maintenance materials, and related accessories in the United States. The Tile Shop offers a wide selection of high-quality products, exclusive designs, knowledgeable staff and exceptional customer service in an extensive showroom environment. The Tile Shop currently operates 141 stores in 31 states and the District of Columbia. The Tile Shop is a proud member of the American Society of Interior Designers (ASID), National Association of Homebuilders (NAHB), National Kitchen and Bath Association (NKBA), and the National Tile Contractors Association (NTCA). For more information, visit Join The Tile Shop (#thetileshop) on Instagram, TikTok, Facebook, Pinterest and YouTube.
Globe and Mail
2 hours ago
- Globe and Mail
Relapsing-Remitting Multiple Sclerosis Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment
DelveInsight's, 'Relapsing-Remitting Multiple Sclerosis Pipeline Insight 2025' report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Relapsing-Remitting Multiple Sclerosis pipeline landscape. It covers the Relapsing-Remitting Multiple Sclerosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Relapsing-Remitting Multiple Sclerosis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Stay ahead with the latest insights! Download DelveInsight's comprehensive Relapsing-Remitting Multiple Sclerosis Pipeline Report to explore emerging therapies, key Relapsing-Remitting Multiple Sclerosis Companies, and future Relapsing-Remitting Multiple Sclerosis treatment landscapes @ Relapsing-Remitting Multiple Sclerosis Pipeline Outlook Report Key Takeaways from the Relapsing-Remitting Multiple Sclerosis Pipeline Report In June 2025, Novartis Pharmaceuticals announced a study will evaluate if relapsing-remitting MS patients that have not had a relapse in the past year would benefit from a switch to ofatumumab versus staying on their continued current therapy. This study will also look at whether an elevated serum neurofilament light (NfL) level predicts enhanced benefit from a switch to ofatumumab. In June 2025, Celgene conducted a study is to evaluate the effectiveness, safety, tolerability, drug levels and drug effects of ozanimod compared to fingolimod in children and adolescents with relapsing remitting multiple sclerosis (RRMS). DelveInsight's Relapsing-Remitting Multiple Sclerosis pipeline report depicts a robust space with 20+ active players working to develop 22+ pipeline therapies for Relapsing-Remitting Multiple Sclerosis treatment. The leading Relapsing-Remitting Multiple Sclerosis Companies such as Immunic AG, Sanofi, Anokion, RemeGen, HuniLife Biotechnology, Biogen, Clene Nanomedicine, Novartis, Celltrion, Imcyse SA, Takeda and others. Promising Relapsing-Remitting Multiple Sclerosis Therapies such as TMP001, Rebif®, Avonex®, dimethyl fumarate, BAF312, IMCY-0141, Ocrelizumab, and others. Discover how the Relapsing-Remitting Multiple Sclerosis treatment paradigm is evolving. Access DelveInsight's in-depth Relapsing-Remitting Multiple Sclerosis Pipeline Analysis for a closer look at promising breakthroughs @ Relapsing-Remitting Multiple Sclerosis Clinical Trials and Studies Relapsing-Remitting Multiple Sclerosis Emerging Drugs Profile IMU-838: Immunic AG Vidofludimus calcium is an orally administered investigational small molecule drug being developed for chronic inflammatory and autoimmune diseases, currently in late-stage clinical trials for multiple sclerosis (MS). Uniquely, vidofludimus calcium's first-in-class, dual mode of action combines neuroprotective, anti-inflammatory and anti-viral effects to target the complex pathophysiology of MS. As a selective immune modulator, it activates the neuroprotective transcription factor, nuclear receptor-related 1 (Nurr1), which provides direct and indirect neuroprotective effects. Additionally, vidofludimus calcium achieves anti-inflammatory and anti-viral effects through highly selective inhibition of the enzyme dihydroorotate dehydrogenase (DHODH). Currently, the drug is in Phase III stage of its development for the treatment of Relapsing-Remitting Multiple Sclerosis. IMCY-0141: Imcyse SA IMCY-0141 Imotope™ is designed based on MOG (Myelin Oligodendrocyte Glycoprotein) with the aim to halt the progression of multiple sclerosis (MS) by stopping the body's immune system from attacking the central nervous system and disrupting undesirable autoimmune responses that drive the destruction of the myelin sheath protecting the nerves. IMCY-0141 has shown promising results in several MS preclinical models, demonstrating an immune response that supports the proposed mode of action and inducing a memory response so that the treatment effect is long-lasting and requires less frequent dosing regimens. Also, if treatment is begun early enough, it has the potential to allow patients to live with minimal impact from the disease. Currently, the drug is in Phase I/II stage of its development for the treatment of Relapsing-Remitting Multiple Sclerosis. ANK-700: Anokion SA ANK-700 is an investigational therapy developed by Anokion for the treatment of Relapsing-Remitting Multiple Sclerosis (RRMS). It employs a novel approach known as an ""inverse vaccine,"" aiming to re-educate the immune system to recognize specific myelin proteins as ""self,"" thereby preventing autoimmune attacks on the central nervous system. This strategy seeks to reduce neuroinflammation while preserving overall immune function. Anokion's approach utilizes its proprietary immune tolerance platform, which targets natural pathways in the liver to restore immune tolerance. This liver-targeted antigen strategy effectively expands antigen-specific regulatory T-cells in vivo, offering therapeutic potential across various inflammatory conditions, including multiple sclerosis. ANK-700's innovative mechanism and encouraging early clinical data position it as a promising candidate for future disease-modifying therapies in RRMS. Currently, the drug is in Phase I stage of its development for the treatment of Relapsing-Remitting Multiple Sclerosis. The Relapsing-Remitting Multiple Sclerosis pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of Relapsing-Remitting Multiple Sclerosis with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Relapsing-Remitting Multiple Sclerosis Treatment. Relapsing-Remitting Multiple Sclerosis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Relapsing-Remitting Multiple Sclerosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Relapsing-Remitting Multiple Sclerosis market. Get a detailed analysis of the latest innovations in the Relapsing-Remitting Multiple Sclerosis pipeline. Explore DelveInsight's expert-driven report today! @ Relapsing-Remitting Multiple Sclerosis Unmet Needs Relapsing-Remitting Multiple Sclerosis Companies Immunic AG, Sanofi, Anokion, RemeGen, HuniLife Biotechnology, Biogen, Clene Nanomedicine, Novartis, Celltrion, Imcyse SA, Takeda and others. Relapsing Remitting multiple sclerosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Intravenous Subcutaneous Parenteral Topical Relapsing-Remitting Multiple Sclerosis Products have been categorized under various Molecule types such as Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Download DelveInsight's latest report to gain strategic insights into upcoming Relapsing-Remitting Multiple Sclerosis Therapies and key Relapsing-Remitting Multiple Sclerosis Developments @ Relapsing-Remitting Multiple Sclerosis Market Drivers and Barriers, and Future Perspectives Scope of the Relapsing-Remitting Multiple Sclerosis Pipeline Report Coverage- Global Relapsing-Remitting Multiple Sclerosis Companies- Immunic AG, Sanofi, Anokion, RemeGen, HuniLife Biotechnology, Biogen, Clene Nanomedicine, Novartis, Celltrion, Imcyse SA, Takeda and others. Relapsing-Remitting Multiple Sclerosis Therapies- TMP001, Rebif®, Avonex®, dimethyl fumarate, BAF312, IMCY-0141, Ocrelizumab, and others. Relapsing-Remitting Multiple Sclerosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Relapsing-Remitting Multiple Sclerosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Which companies are leading the race in Relapsing-Remitting Multiple Sclerosis drug development? Find out in DelveInsight's exclusive Relapsing-Remitting Multiple Sclerosis Pipeline Report—access it now! @ Relapsing-Remitting Multiple Sclerosis Emerging Drugs and Major Companies Table of Content Introduction Executive Summary Relapsing-Remitting Multiple Sclerosis: Overview Pipeline Therapeutics Therapeutic Assessment Relapsing-Remitting Multiple Sclerosis– DelveInsight's Analytical Perspective Late Stage Products (Phase III) IMU-838: Immunic AG Drug profiles in the detailed report….. Mid Stage Products (Phase II) Telitacicept: RemeGen Drug profiles in the detailed report….. Early Stage Products (Phase I) ANK700: Anokion Drug profiles in the detailed report….. Preclinical and Discovery Stage Products Drug name: Company name Drug profiles in the detailed report….. Inactive Products Relapsing-Remitting Multiple Sclerosis Key Companies Relapsing-Remitting Multiple Sclerosis Key Products Relapsing-Remitting Multiple Sclerosis- Unmet Needs Relapsing-Remitting Multiple Sclerosis- Market Drivers and Barriers Relapsing-Remitting Multiple Sclerosis- Future Perspectives and Conclusion Relapsing-Remitting Multiple Sclerosis Analyst Views Relapsing-Remitting Multiple Sclerosis Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
